Canlyniadau Chwilio - Keith Usiskin

  • Dangos 1 - 17 canlyniadau o 17
Mireinio'r Canlyniadau
  1. 1
    Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)

    Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR) gan Matthew R. Weir, Irina Kline, John Xie, Robert Edwards, Keith Usiskin

    Cyhoeddwyd 2014
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

    Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes gan Julio Rosenstock, Naresh Aggarwal, David Polidori, Yue Zhao, Deborah Arbit, Keith Usiskin, George Capuano, William Canovatchel

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

    Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus gan Nelson B. Watts, John P. Bilezikian, Keith Usiskin, Robert Edwards, Mehul Desai, Gordon Law, Gary Meininger

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

    Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise gan Kaj Stenlöf, William T. Cefalu, Kyung‐Ah Kim, Maria Alba, Keith Usiskin, C. Tong, William Canovatchel, Gary Meininger

    Cyhoeddwyd 2012
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin

    Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin gan John P. Bilezikian, Nelson B. Watts, Keith Usiskin, David Polidori, Albert Fung, Daniel J. Sullivan, Norm Rosenthal

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn’s Disease

    Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn’s Disease gan Brian G. Feagan, Bruce E. Sands, Guillermo Rossiter, Bin Li, Keith Usiskin, Xiaojiang Zhan, Jean‐Frédéric Colombel

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directions

    Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directions gan Harris A. Ahmad, James E. East, Remo Panaccione, Simon Travis, James B. Canavan, Keith Usiskin, Michael F. Byrne

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

    Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies gan Alan J. Sinclair, Bruce W. Bode, Stewart B. Harris, Ujjwala Vijapurkar, Cristiana Mayer, Albert Fung, Wayne Shaw, Keith Usiskin, Mehul Desai, Gary Meininger

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes

    Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes gan William T. Cefalu, Kaj Stenlöf, Lawrence A. Leiter, John Wilding, Lawrence Blonde, David Polidori, John Xie, Daniel J. Sullivan, Keith Usiskin, William Canovatchel, Gary Meininger

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

    Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial gan John Wilding, G. Charpentier, Priscilla Hollander, Guillermo González-Gálvez, Chantal Mathieu, Frank Vercruysse, Keith Usiskin, Ga‐Lai Law, Simon Black, William Canovatchel, Gary Meininger

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

    Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease gan J.‐F. Yale, George L. Bakris, Bertrand Cariou, Dennis K. Yue, Elias David‐Neto, Liwen Xi, K. Figueroa, Ewa Wajs, Keith Usiskin, Gary Meininger

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy

    Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy gan Hala Yamout, Vlado Perkovic, Melanie J. Davies, Vincent Woo, Dick de Zeeuw, Cristiana Mayer, Ujjwala Vijapurkar, Irina Kline, Keith Usiskin, Gary Meininger, George L. Bakris

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis

    Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis gan Silvio Danese, Markus F. Neurath, Adam Kopoń, Salam Zakko, Timothy Simmons, Ronald Fogel, Corey A. Siegel, Remo Panaccione, Xiaojiang Zhan, Keith Usiskin, Denesh K. Chitkara

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments

    Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments gan Klaus Gottlieb, Marco Daperno, Keith Usiskin, Bruce E. Sands, Harris A. Ahmad, Colin W. Howden, William E. Karnes, Young S. Oh, Irene Modesto, Colleen Marano, Ryan W. Stidham, Walter Reinisch

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study

    Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study gan William J. Sandborn, Brian G. Feagan, Stephen B. Hanauer, Séverine Vermeire, Subrata Ghosh, Wenzhong J. Liu, AnnKatrin Petersen, Lorna Charles, Vivian Huang, Keith Usiskin, Douglas C. Wolf, Geert D’Haens

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

    Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis gan William J. Sandborn, Brian G. Feagan, Geert D’Haens, Douglas C. Wolf, Igor Jovanović, Stephen B. Hanauer, Subrata Ghosh, AnnKatrin Petersen, Steven Y. Hua, Ji Hwan Lee, Lorna Charles, Denesh K. Chitkara, Keith Usiskin, Jean–Frédéric Colombel, Loren Laine, Silvio Danese

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    Genetic architecture of human plasma lipidome and its link to cardiovascular disease

    Genetic architecture of human plasma lipidome and its link to cardiovascular disease gan Rubina Tabassum, Joel Rämö, Pietari Ripatti, Jukka Koskela, Mitja Kurki, Juha Karjalainen, Priit Palta, Shabbeer Hassan, Javier Núñez-Fontarnau, Tuomo Kiiskinen, Sanni Söderlund, Niina Matikainen, Mathias J. Gerl, Michał A. Surma, Christian Klose, Nathan O. Stitziel, Hannele Laivuori, Aki S. Havulinna, Susan K. Service, Veikko Salomaa, Matti Pirinen, Anu Jalanko, Jaakko Kaprio, Kati Donner, Mari Kaunisto, Nina Mars, Alexander Dada, Anastasia Shcherban, Andrea Ganna, Arto Lehistö, Elina Kilpeläinen, Georg Brein, Awaisa Ghazal, Jarmo Harju, Kalle Pärn, Pietro Della Briotta Parolo, Risto Kajanne, Susanna Lemmelä, Timo P. Sipilä, Tuomas Sipilä, Ulrike Lyhs, Vincent Llorens, Teemu Niiranen, Kati Kristiansson, Lotta Männikkö, Manuel González Jiménez, Markus Perola, Regis Wong, Terhi Kilpi, Tero Hiekkalinna, Elina Järvensivu, Essi Kaiharju, Hannele Mattsson, Markku Laukkanen, Päivi Laiho, Sini Lähteenmäki, Tuuli Sistonen, Sirpa Soini, Adam Ziemann, Anne Lehtonen, Apinya Lertratanakul, Bob Georgantas, Bridget Riley‐Gillis, Danjuma Quarless, Fedik Rahimov, Graham Heap, Howard J. Jacob, Jeffrey F. Waring, J. Wade Davis, Nizar Smaoui, Relja Popovic, Sahar Esmaeeli, Jeff Waring, Athena Matakidou, Ben Challis, David A. Close, Slavé Petrovski, Antti Karlsson, Johanna Schleutker, Kari Pulkki, Petri Virolainen, Lila Kallio, Graham J. Mann, Sami Heikkinen, Veli‐Matti Kosma, Chia‐Yen Chen, Heiko Runz, Jiang Liu, Paola G. Bronson, Sally John, Sanni Lahdenperä, Susan Eaton, Wei Zhou, Minna Hendolin, Outi Tuovila, Raimo Pakkanen, Joseph Maranville, Keith Usiskin, Marla Hochfeld, Robert Plenge

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: